Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Pembrolizumab is indicated for the treatment of patients with metastatic Small-Cell-Lung-Cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy
On June 17, 2019, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy based on NCT02054806 and NCT02628067 - KEYNOTE-158 - Pembrolizumab in Advanced Solid Tumors
see also:
[Immune Checkpoint Inhibitors (ICIs) …